PHMMF (Pharma Mar) Gross-Profit-to-Asset % : 48.64% (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Pharma Mar Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharma Mar's annualized Gross Profit for the quarter that ended in Jun. 2024 was $171.3 Mil. Pharma Mar's average Total Assets over the quarter that ended in Jun. 2024 was $352.1 Mil. Therefore, Pharma Mar's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 48.64%.

Pharma Mar Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharma Mar's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Gross-Profit-to-Asset % Chart

Pharma Mar Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

56.33

115.38

58.95

46.48

41.12

Pharma Mar Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															48.70	38.47	44.61	42.87	48.64

Competitive Comparison of Pharma Mar's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharma Mar's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Gross-Profit-to-Asset % falls into.

Pharma Mar Gross-Profit-to-Asset % Calculation

Pharma Mar's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	161.985	/	( (416.588	+	371.341)	/ 2 )
	=	161.985	/	393.9645
	=	41.12 %

Pharma Mar's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2024 )	/	( (Total Assets (Q: Mar. 2024 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	171.264	/	( (362.933	+	341.337)	/ 2 )
	=	171.264	/	352.135
	=	48.64 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Pharma Mar Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Mar Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (OTCPK:PHMMF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

0RC6:UK PHM:Spain PMRA:Germany PMRA:Germany

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.